Next Article in Journal
The AKI-to-CKD Transition: The Role of Uremic Toxins
Next Article in Special Issue
The Interplay of Permeability, Metabolism, Transporters, and Dosing in Determining the Dynamics of the Tissue/Plasma Partition Coefficient and Volume of Distribution—A Theoretical Investigation Using Permeability-Limited, Physiologically Based Pharmacokinetic Modeling
Previous Article in Journal
GPX3 Variant Genotype Affects the Risk of Developing Severe Forms of COVID-19
Previous Article in Special Issue
Host Genetic Background Effect on Body Weight Changes Influenced by Heterozygous Smad4 Knockout Using Collaborative Cross Mouse Population
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 22
10.3390/ijms242216153
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synergic Action of Systemic Risedronate and Local Rutherpy in Peri-implantar Repair of Ovariectomized Rats: Biomechanical and Molecular Analysis

by
Bruna Kaori Namba Inoue
1,
Laura Vidoto Paludetto
1,
Naara Gabriela Monteiro
1,
Fábio Roberto de Souza Batista
1,
Igor Lebedenco Kitagawa
2,
Roberto Santana da Silva
3,
Cristina Antoniali
1,
Paulo Noronha Lisboa Filho
4 and
Roberta Okamoto
1,*
1
Department of Basic Sciences, Araçatuba Dental School, São Paulo State University Júlio de Mesquita Filho—UNESP, Aracatuba 16015-050, SP, Brazil
2
Federal Institute of Education, Science and Technology of São Paulo (IFSP), Birigui 16201-407, SP, Brazil
3
Department of Biomolecular Sciences, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo—USP, Ribeirão Preto 14040-403, SP, Brazil
4
Department of Physics and Meteorology, Bauru Sciences School, São Paulo State University Júlio de Mesquita Filho—UNESP, Bauru 17033-360, SP, Brazil
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(22), 16153; https://doi.org/10.3390/ijms242216153
Submission received: 27 September 2023 / Revised: 3 November 2023 / Accepted: 7 November 2023 / Published: 10 November 2023
(This article belongs to the Collection 21st Anniversary of IJMS: Advances in Molecular Endocrinology and Metabolism)
Browse Figures
Versions Notes

Abstract

:
Postmenopausal osteoporosis and poor dietary habits can lead to overweightness and obesity. Bisphosphonates are the first-line treatment for osteoporosis. However, some studies show that they may increase the risk of osteonecrosis of the jaw. Considering the antimicrobial, angiogenic and vasodilatory potential of nitric oxide, this study aims to evaluate the local activity of this substance during the placement of surface-treated implants. Seventy-two Wistar rats were divided into three groups: SHAM (SHAM surgery), OVX + HD (ovariectomy + cafeteria diet), and OVX + HD + RIS (ovariectomy + cafeteria diet + sodium risedronate treatment), which were further subdivided according to the surface treatment of the future implant: CONV (conventional), TE10, or TE100 (TERPY at 10 or 100 μM concentration); n = 8 per subgroup. The animals underwent surgery for implant installation in the proximal tibia metaphysis and were euthanized after 28 days. Data obtained from removal torque and RT-PCR (OPG, RANKL, ALP, IBSP and VEGF expression) were subjected to statistical analysis at 5% significance level. For biomechanical analysis, TE10 produced better results in the OVX + HD group (7.4 N/cm, SD = 0.6819). Molecular analysis showed: (1) significant increase in OPG gene expression in OVX groups with TE10; (2) decreased RANKL expression in OVX + HD + RIS compared to OVX + HD; (3) significantly increased expressions of IBSP and VEGF for OVX + HD + RIS TE10. At its lowest concentration, TERPY has the potential to improve peri-implant conditions.

1. Introduction

The aging of the world’s population because of improved quality of life and increased life expectancy has raised new concerns about the care of the elderly, who are more prone to the development of various diseases. Osteoporosis is one of the most prevalent chronic diseases in this age group and is characterized by a reduction in bone mineral density and microarchitectural deterioration of this tissue, leading to increased fracture risk due to bone fragility [1,2].
The highest risk group is over 50 years of age, and although there is some incidence in men [3], records from the International Osteoporosis Foundation (2009) indicate a greater predilection for this disease in women, with up to 30% of the female population affected [4]. This is due to the hormonal changes that occur during the postmenopausal period, following a decrease in estrogen levels and an imbalance in bone turnover [5,6], causing resorptive processes to predominate over those of bone formation.
The postmenopausal period may also be associated with a change in the lifestyle of the population, which often becomes sedentary and involves poor dietary habits [7]. During this period, with the loss of the protective role of estrogen and the consequent increase in circulating androgens, the distribution of body fat may also change [8], leading to the development of abdominal obesity and metabolic syndrome [9,10,11].
However, studies on the relationship between obesity and osteoporosis remain controversial [9,12,13,14,15,16]. While some suggest that obesity and overweightness may have a protective effect on bone tissue [17], others suggest that the chronic inflammation induced by the accumulation of lipids due to hypercaloric and/or hyperlypidic diets stimulates the synthesis of pro-inflammatory cytokines (such as TNF-α, IL-1þ, IL-6, CRP, leptin, and adiponectin), leading to bone loss in response to the stimulation of osteoclastic differentiation and consequent bone resorption through the activation of the RANKL/RANK/OPG signaling pathway [18,19,20,21,22,23].
In attempts to improve bone quality, various medications have been administered. Suggested pharmacological therapy for osteoporosis involves the use of drugs classified as antiresorptive or anabolic agents. Indicated as first-line treatment [24,25], bisphosphonates are classified as antiresorptive agents, whose performance is to inhibit the differentiation and activity of osteoclasts [26,27]. Among the bisphosphonates, risedronate is noteworthy for its efficacy in combating bone loss caused by osteoporosis in women during the postmenopausal period [28]. It contributes to increased bone density by reducing the number, viability, and activity of osteoclasts and their precursors [29].
Despite their great antiresorptive potential, the use of bisphosphonates remains controversial because of the increased risk of osteonecrosis of the jaw in long-term treatment [30]. Bone damage has been observed in studies of osteoporotic rats treated with sodium alendronate, where prolonged use of this drug caused damage to the alveolar and peri-implant bone repair processes, with a decrease in bone turnover and a negative impact on the quality of bone produced around implants [31,32,33].
As a result, alternative pharmacological therapies [34], such as raloxifene, calcitonin, and teriparatide [35], among others, have been introduced in the search for results with less damage to peri-implant bone repair. However, even under favorable conditions for bone repair, prolonged systemic treatment with these drugs resulted in more startling adverse effects than those seen with bisphosphonate therapy [36,37,38,39].
While maintaining pharmacological therapy with bisphosphonates, a way to locally improve bone repair and osseointegration processes is sought through implant surface treatment. In the context of the continuous development of substances aimed at optimizing the quality of bone tissue and the referred processes, the use of a nitric oxide donor was proposed. This compound, Rutherpy [Ru(terpy)(bdq)NO+]3+ (TERPY), was developed in the Chemical Laboratory of the Faculty of Pharmacy and Biochemistry of Ribeirão Preto/USP. Being a nitrosylated metal compound, TERPY can release nitric oxide enzymatically or without a specific biological target in the presence of vascular tissue and reducing agents or by light irradiation [40,41,42].
Nitric oxide is essential for several body mechanisms, especially due to its antimicrobial, vasodilator, and angiogenic properties and its activity in stimulating collagen production [43]; it also has a modulating role in osteoblastic differentiation [44,45,46], which is essential for bone repair and remodeling in the peri-implant region.
In the search for new methods to minimize the consequences of implant placement in individuals with reduced bone repair capacity, it is necessary to evaluate the effect of surface treatment with TERPY on the maximum repair response of peri-implant bone.

2. Results

2.1. Clinical Data

Regarding the weights of the animals, the three groups showed statistically significant differences (p < 0.05) between T1–T2 and T1–T3. For blood glucose, the OVX + HD + RIS group, in the interval between T1 and T2, was the only one with significant differences (p < 0.05). For the Lee index, both groups with systemic involvement (OVX + HD and OVX + HD + RIS) showed statistical differences between T1 and T2 and between T1 and T3, as shown in the Figure 1.

2.2. Biomechanical Analysis (Counter-Torque)

In the SHAM and OVX + HD + RIS groups, there was no statistically significant difference between the different implant types. In the OVX + HD group, the TERPY 10 μM (TE10) concentration brought better results, with a statistically significant difference between the CONV-TE10 (p < 0.05) and TE10-TE100 (p < 0.05) surfaces, as shown in Figure 2.

2.3. Molecular Analysis (Real-Time PCR)

In the SHAM group, there was a statistically significant difference in OPG gene expression between the CONV-TE100 surfaces (p < 0.05). There were also differences between TE10-CONV and TE10-TE100 in the OVX + HD group, and between TE10-CONV and TE10-TE100 (always with p < 0.05) in the OVX + HD + RIS group, as shown in Figure 3.
For the RANKL gene, the SHAM group showed no statistical difference between the three types of surfaces. However, these differences were noticeable in the OVX + HD and OVX + HD + RIS groups (between CONV-TE10, CONV-TE100, and TE10-TE100, in both situations and always with p < 0.05), as shown in Figure 4.
For the ALP gene, the SHAM and OVX + HD + RIS groups showed statistically significant differences between the CONV-TE10, CONV-TE100, and TE10-TE100 surfaces (p < 0.05. As for OVX + HD, the difference applied between CONV-TE10 and CONV-TE100 (p < 0.05), as shown in Figure 5.
For the IBSP gene, the collected data from the SHAM group indicate that there was a statistically significant difference between the CONV-TE10, CONV-TE100, and TE10-TE100 surfaces (p < 0.05). In OVX + HD animals, differences can be noted between the CONV-TE10 and CONV-TE100 groups (p < 0.05), whereas in OVX + HD + RIS, a statistical difference occurred between CONV-TE100 and TE10-TE100 (p < 0.05), as shown in Figure 6.
In the SHAM and OVX + HD + RIS groups, there were statistically significant differences in relative gene expression for VEGF between the CONV-TE10 and TE-TE100 groups (p < 0.05). The OVX + HD group, on the other hand, showed no significant differences, as shown in Figure 7.

3. Discussion

In the analysis of the clinical data of the animals, although the three studied groups showed statistically significant differences at the beginning and the end of the experiment (between T1 and T2 and between T2 and T3, with p < 0.05), it was observed that the weight gain of the ovariectomized animals was more pronounced: the initial weights of the three groups were in the range of 200 to 250 g, but at the end of the experiment the SHAM group had a weight close to 300 g, while the OVX + HD and OVX + HD + RIS animals exceeded the average of 400 g. There were no major differences between the blood glucose levels of the SHAM and OVX + HD groups during the experiment. Only the OVX + HD + RIS group showed something significant between periods T1 and T2. Finally, the Lee index of the animals brought more remarkable data: only the OVX animals showed statistically significant differences at the end of the experiment (T1–T2 and T1–T3), suggesting an increase in the abdominal circumference of these animals.
The changes in body weight and Lee index of the animals can be explained by the association of the cafeteria diet (hyperlipidemic) with the depletion of estrogen levels resulting from the surgical procedure of ovariectomy, which mimicked the postmenopausal period in humans. During this period, in addition to the loss of the protective role of estrogen on the skeletal system, there is an increase in circulating androgens, leading to changes in body fat distribution that favor an accumulation of abdominal fat [8,47,48,49]. It is worth mentioning that although the animals did not show large variations in their glycemia, insulin resistance is a very common factor observed in overweight or obese people, and if not controlled, can lead to consequences such as type 2 diabetes [18,20,50]. In addition, studies have shown that overweightness in Wistar rats is commonly associated with increased blood pressure, insulin resistance, hyperglycemia, hyperinsulinemia, hyperleptinemia, and dyslipidemia [51]. Most probably, the animals in these studies were suffering from metabolic syndrome, but this cannot be confirmed because lipid profile measurements were not performed; only changes in weight and Lee’s index were observed and documented.
In the biomechanical analysis, whether the surface of the implants was treated made no difference for the SHAM and OVX + HD + RIS groups. Only the OVX + HD group presented a better result for the TERPY 10 μM surface treatment compared to the others. Another pertinent fact emerged when comparing the difference in mean removal torque between the SHAM and ovariectomized groups. The purpose of the removal torque analysis was to evaluate the quality of the osseointegration between bone and implant. In this way, it was observed that this was another point that was affected by the decrease in estrogen production, since the OVX groups had lower mean removal torques. Estrogen deficiency induces changes in the bone by promoting the prevalence of resorptive processes over bone formation, producing more porous bone tissue of lower quality and mineral density [52,53,54,55,56], which results in lower osseointegration, and consequently delaying the bone repair process. The removal torque data of the OVX + HD + RIS group were superior to those of the group without systemic treatment (except for the implant surface treated with TERPY 10 μM), probably due to the mechanism of action of risedronate sodium, which inhibits bone marrow adipogenesis and suppresses RANKL expression, inhibiting osteoclast differentiation and improving bone mineral density [57]. On the other hand, the better results of TE10 surface in the OVX + HD group may be explained by the antimicrobial action of nitric oxide, which is effective against bacterial adhesion to the implant surface and prevents the installation of any local infectious process, allowing better osseointegration [58]. Other properties of nitric oxide are the mediation of inflammatory processes, angiogenesis, and tissue remodeling [44,45,46,59]. In addition, studies have indicated that the antibacterial potential of nitric oxide causes a reduction in postoperative edema and erythema after placement of nitric oxide-releasing pins [60].
For the biomolecular analysis, the relative gene expression of OPG, RANKL, ALP, IBSP, and VEGF was analyzed to characterize the effects of nitric oxide release by TERPY present on the surface of the placed implant. Osteoprotegerin (OPG) and RANKL are genes involved in the dynamics of bone tissue remodeling, indicating cellular activity of osteoblasts and osteoclasts in the tissue through the RANK/RANKL/OPG pathway. In contrast, alkaline phosphatase (ALP) indicates osteoblastic activity and the mineralization process and hydroxyapatite crystal quality, while vascular endothelial growth factor (VEGF) and integrin-binding sialoprotein (IBSP) indicate angiogenic activity (vessel proliferation) and the bone mineralization process, respectively.
Under normal conditions, where there is no estrogen deprivation (SHAM), the relative gene expression of ALP, IBSP, and VEGF was higher in the groups that received implants functionalized with TERPY at both concentrations, suggesting that the compound may favor osteoblastic activity and bone formation processes. Some previous experiments in osteoblast cultures have shown that exogenous nitric oxide can lead to increased osteoblast numbers and osteocalcin production [61,62,63], contributing to bone matrix mineralization.
The TE10 surface promoted increased relative OPG gene expression in OVX + HD animals without necessarily reducing RANKL expression. In OVX + HD + RIS animals, the same increase in OPG was seen, but a reduction in RANKL protein expression was noted. This reaffirms the inhibitory role of bisphosphonates on osteoclastic activity and resorptive processes [28,29], and suggests that TE has an association with OPG expression, promoting osteoblast proliferation and development [61,62]. In the latter group [OVX + HD + RIS TE10], although no increase in ALP was found, significantly increased levels of IBSP and VEGF were found, indicating bone matrix formation and mineralization at these sites.
On the other hand, under the action of TERPY at its lowest concentration, the high gene expression of OPG and RANKL in the OVX + HD group indicated intense cellular activity, both of osteoblasts and osteoclasts, in a constant process of bone remodeling.
The possibility of nitric oxide stimulating the development of osteoblasts was strengthened by the difference between the relative gene expression of OPG and RANKL in the OVX + HD + RIS group, especially under the concentration of 10 μM of TERPY on the implant surface. Together with the action of risedronate sodium, which suppresses bone resorptive processes and osteoclastic activity by inhibiting RANKL synthesis, both variables contributed to the expression of OPG over RANKL, indicating the prevalence of osteoblastic activities over osteoclastic ones.
In groups with at least one of the systemic conditions presented in this study, implants with surfaces treated with TERPY 100 μM did not perform as well as those treated with TERPY at the lowest concentration, suggesting that there may be some level of toxicity when higher concentrations of nitric oxide are present. Studies in cell cultures have shown that the beneficial effects of nitric oxide can be reversed at high concentrations and rapid release rates, potentially leading to apoptosis of these cells [63,64,65,66,67].

4. Methods and Materials

4.1. Animals

With the approval of the Research Ethics Committee on the Use of Animals of the Faculty of Dentistry of Araçatuba-UNESP (FOA process n° 00563-2018), 72 female rats (Rattus norgicus albinus, Wistar), 3 months old, were used in this study.
Initially, the rats underwent an estrous cycle assessment to ensure that they were cycling normally. For this, the animals were placed in individual cages, and 1 or 2 drops of saline solution were introduced into the vagina daily, which were then aspirated and placed on a histological slide for immediate microscopic reading (Long & Evans technique, 1922) to enable detection of the 4 phases of the estrous cycle. After 2 to 3 regular estrous cycles were observed, the appropriate animals were selected.
The rats were divided into experimental groups according to the type of systemic disorder, diet, and drug treatment (SHAM, OVX + HD and OVX + HD + RIS), and also into subgroups according to the type of implant to be installed (CONV, TERPY 10 μM, and TERPY 100 μM), as explained in Table 1.

4.2. High-Fat Diet

The SHAM group received chow (NUVILAB, 1.4% Ca and 0.9% P) and water ad libitum, while the OVX + HD and OVX + HD + RIS groups were fed a high-fat diet (cafeteria diet) throughout the experiment, consisting of daily weighed amounts of stuffed crackers, wafers, and corn chips, totaling 30 g per animal. A bottle of water containing 12% sucrose was also provided, as described in Table 2.

4.3. Clinical Data Collection

To follow the development of metabolic changes in the animals, clinical data such as weight, blood glucose, and Lee index of each animal were obtained at 3 different times: before SHAM or bilateral ovariectomy surgery (T1), before the installation of the tibial implants (T2), and before the animals were euthanized (T3).

4.4. Fictitious Surgery and Bilateral Ovariectomy Surgery

Rats in the OVX + HD and OVX + HD + RIS groups were anesthetized with 5 mg/kg intramuscular xylazine hydrochloride (Xylazine—Coopers, Paulínia, SP, Brazil, Ltda.) and 50 mg/kg intramuscular ketamine hydrochloride (Injectable Ketamine Hydrochloride, Fort Dodge, Saúde Animal Ltda, Campinas, SP, Brazil.) and then immobilized on a surgical board in lateral decubitus position. A 1 cm incision was made on the flanks, separating the subcutaneous tissue and then the peritoneum to gain access to the abdominal cavity. Once the ovaries and uterine horns were located, they were sutured with Polyglactin 910 4.0 (Vicryltm—Jhonson & Jhonson, New Brunswick, NJ, USA) for subsequent removal of the ovaries. At the end, the suture was made by planes with Polyglactin 910 4.0 thread (Vicryltm—Jhonson & Johnson, New Brunswick, NJ, USA).
SHAM group rats underwent the same procedure, but only to the point of surgical exposure of the uterine horns and ovaries, without their respective laceration and removal.

4.5. Systemic and Local Drug Treatments

4.5.1. Systemic Treatment with Risedronate Sodium

Thirty days after SHAM and bilateral ovariectomy, the OVX + HD + RIS group began treatment with risedronate sodium (ApothiMed Ltda., Araçatuba, SP, Brazil) at 35 mg/kg. The drug was diluted in saline solution and administered weekly by gavage using a curved gavage needle (Insight equipment) until the end of the experiment. Animals in the SHAM and OVX + HD groups received the vehicle (saline) only during the same period.

4.5.2. Implant Surface Functionalization with TERPY

The surface functionalization of the TERPY 10 μM and TERPY 100 μM implants was performed using the “layer by layer” technique, under the guidance of Associate Prof. Paulo Noronha Lisboa-Filho. This technique consists in immersing a solid substrate, whose surface has a certain charge imbalance, for a certain time in an aqueous solution containing the material to be deposited. The charge of the material must be opposite to that of the substrate for adsorption by electrostatic attraction to occur. The substrate + monolayer is then washed to remove excess material and dried with compressed air, nitrogen, or a fan, to be immersed in a new solution, now with an opposite charge to the last one. In this way, ultrathin films are formed consisting of cationic and anionic molecular bilayers that are alternately adsorbed. The new substrate + bilayer assembly is then washed and can be dried again.
For the formation of the multilayers, as shown in Figure 8, the sulfonated polystyrene electrolyte (PSS, negatively charged), in which TERPY (concentrations of 10 μM and 100 μM) was dispersed, and a TiO2 electrolyte solution (positively charged), previously prepared by the sol-gel method, were used.
The layer-by-layer technique for functionalizing implants is protected by a patent. More information can be found in Section 6.
A total of 48 implants were functionalized, with 24 in 10 μM TERPY and another 24 in 100 μM.

4.6. Implant Installation

Thirty days after the start of risedronate sodium administration (60 days after SHAM and bilateral ovariectomy), the animals underwent tibial implantation surgery. Rats were fasted for 8 h prior to surgery and then sedated with a combination of 50 mg/kg intramuscular ketamine (Vetaset—Fort Dodge Saúde Animal Ltda, Campinas, São Paulo, Brazil) and 5 mg/kg xylazine hydrochloride (Dopaser—Laboratório Calier do Brasil Ltda—Osasco, São Paulo, Brazil).
After sedation, the medial portion of the tibia was trichotomized and antisepsis of the region was performed by polyvinylpyrrolidone iodine degerming (PVPI 10%) prior to the incision, which was made with a number 15 bistoury blade measuring 3 cm in length in the proximal tibial metaphysis. The soft tissue was then divulsed in full thickness and pulled apart with the aid of periosteal detachers, exposing the bone to receive the implants.
A total of 72 commercially pure grade IV titanium implants were used, with a diameter of 2 mm and a height of 4 mm, having been surface treated by double acid etching (nitric, hydrofluoric, and sulfuric acids), sterilized by gamma rays, and either subjected or not subjected to surface functionalization with both concentrations of TERPY (10 μM and 100 μM). Milling was performed with a 1.3 mm diameter spiral burr mounted on an electric motor (BLM 600®; Driller, São Paulo, SP, Brazil) at a speed of 1000 rpm under irrigation with isotonic 0.9% sodium chloride solution (Fisiológico®, Laboratórios Biosintética Ltda®, Ribeirão Preto, SP, Brazil) and a 20:1 reduction contra-angle (3624N 1:4 angle piece, 67RIC 1:4 head, KaVo®, Kaltenbach & Voigt GmbH & Co., Biberach, Germany) with a depth of 3.0 mm, with initial locking and stability. Installation was performed manually using a digital key.
Each animal received 1 implant in the region of the proximal tibial metaphysis, and later the tissues were sutured in layers using absorbable yarn (Polygalactin 910—Vycrill 4.0) with continuous stitches in the deep plane and monofilament yarn (Nylon 5.0) with interrupted stitches in the outermost plane. In the immediate postoperative period, each animal received a single intramuscular dose of 0.2 mL of penicillin G-benzathine and dipyrone sodium (1 mg/kg/day) for analgesia.

4.7. Euthanasia

Animals in the SHAM, OVX + HD, and OVX + HD + RIS groups were euthanized 28 days after the implant installation surgery. With the tibiae in vivo, biomechanical removal torque analysis was performed, or samples were collected from the areas of interest for PCR, which were stored in a −80 °C freezer.

4.8. Proposed Analyses

4.8.1. Biomechanical Analysis (Removal Torque)

For removal torque analysis, the implants exposed in the specimens were connected to the digital torque tool. A counterclockwise movement was performed, increasing the removal torque until the implant rotated within the bone tissue and the bone-implant contact was completely broken. The device recorded the maximum peak torque for this fracture in newton-meter (NM), and the values were pooled and subjected to statistical analysis.

4.8.2. Molecular Analysis (Real-Time PCR)

Immediately after removal of the implants from the tibias using reverse torque, the peri-implant bone was collected with mini gouge forceps, maintaining at least 0.5 cm on each side of the peri-implant space and preserving the bone in contact with the implant threads. The bone was carefully washed in phosphate-buffered saline, frozen in liquid nitrogen, and stored at −80 °C to extract the total RNA using a Trizol reagent (Life Technologies: Invitrogen, Carlsbad, CA, USA). After RNA integrity, purity, and concentration analysis, cDNA was created using one µg RNA via a reverse transcriptase reaction (M-MLV reverse transcriptase: Promega Corporation, Madison, WI, USA). Sample cDNA was pipetted onto the array PCR plate with Taqman Fast Advanced Mastermix (Applied Biosystems, Foster City, CA, USA) to detect genes involved in the bone repair process (Taqman Array Fast 96 well plate, Applied Biosystems). Real-time PCR was performed on a Step One Plus real-time PCR detection system (Applied Biosystems) under the following conditions: 50 °C (2 min), 95 °C (10 min), 40 cycles of 95 °C (15 s), and 60 °C (1 min), followed by a standard denaturation curve. The relative gene expression was calculated by referencing the mitochondrial ribosomal protein expression and normalized by the gene expression of tibia fragments undergoing repair during different experimental periods (ΔΔCT method). The assay was performed in quadruplicate, and the genes evaluated were osteoprotegerin (OPG—Tnfrsf11b Rn00563499_m1), receptor activator of nuclear factor kappa B ligand (RANKL—Tnfrsf11 Rn00589289_m1), and alkaline phosphatase (ALP—Rn00564931_m1). Integrin binding sialoprotein (IBSP—Rn00561414_m1) and vascular endothelial growth factor (VEGF—Rn01511602_m1), with Beta-actin (β2-Microglobulin, B2M—Rn00560865_m1) as constitutive, as shown in Table 3.
The values obtained from the proposed analyses were submitted to statistical analysis using GraphPad Prism 7.03 software. The test for homoscedasticity was the Shapiro–Wilk test, and the normal distribution of the data was confirmed for all parameters analyzed. Next, the two-way ANOVA test was performed, considering as factors: systemic condition and time for clinical data; systemic condition and surfaces for counter torque and PCR data. In the sequence, the Tukey post-test was performed with significance level p < 0.05, to indicate the differences between the groups.

5. Conclusions

At its lowest concentration (10 μM), TERPY seems to have the potential to improve peri-implantar conditions, whether in healthy bone tissue or in bone impaired by systemic changes, such as osteoporosis and changes caused by overweight or obesity. The local action of TERPY seems to have an influence on the increase in OPG levels, suggesting a greater osteoblastic activity, and combined with the inhibitory capacity of bisphosphonates on RANKL, it can be said that the placement of functionalized implants in patients using these drugs seems very promising.

6. Patents

BR 10 2021 025891 8 process—“Funcionalização da superfície de implantes com molécula doadora de óxido nítrico através da técnica layer by layer como estratégia para a melhora do processo de reparo periimplantar em ratas”(870210118781 petition).

Author Contributions

Conceptualization, R.O.; data curation, R.O.; formal analysis, B.K.N.I., F.R.d.S.B. and R.O.; funding acquisition, R.O.; investigation, B.K.N.I.; methodology, B.K.N.I., F.R.d.S.B., N.G.M., I.L.K., R.S.d.S., C.A. and P.N.L.F.; project administration, R.O.; resources, R.O.; supervision, R.O.; validation, R.O.; visualization, B.K.N.I., F.R.d.S.B., N.G.M. and R.O.; writing—original draft, B.K.N.I.; writing—review and editing, L.V.P. All authors have read and agreed to the published version of the manuscript.

Funding

This study was financially supported by the São Paulo Research Foundation—FAPESP (process 2020/10462-5). In addition, Roberta Okamoto is affiliated with Research productivity scholarship (process: 309408/2020-2).

Institutional Review Board Statement

The animal study protocol was approved by the Research Ethics Committee on the Use of Animals of the Faculty of Dentistry of Araçatuba-UNESP (FOA process n◦ 00563-2018).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article.

Acknowledgments

We would like to thank Ana Cláudia Ervolino da Silva for functionalizing all the implants used in the research using the layer-by-layer technique.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Harvey, N.; Dennison, E.; Cooper, C. Osteoporosis: Impact on health and economics. Nat. Rev. Rheumatol. 2012, 6, 99–105. [Google Scholar] [CrossRef] [PubMed]
  2. Darcey, J.; Horner, K.; Walsh, T.; Southern, H.; Marjanovic, E.J.; Devlin, H. Tooth loss and osteoporosis: To assess the association between osteoporosis status and tooth number. Br. Dent. J. 2013, 214, E10. [Google Scholar] [CrossRef] [PubMed]
  3. Drake, M.T.; Khosla, S. Male Osteoporosis. Endocrinol. Metab. Clin. N. Am. 2012, 41, 629–641. [Google Scholar] [CrossRef] [PubMed]
  4. International Osteoporis Foundation. IOF Osteoporosis Risk Check. Available online: https://www.osteoporosis.foundation/patients/about-osteoporosis (accessed on 12 March 2023).
  5. Eastell, R.; O’Neill, T.W.; Hofbauer, L.C.; Langdahl, B.; Reid, I.R.; Gold, D.T.; Cummings, S.R. Postmenopausal osteoporosis. Nat. Rev. Dis. Primers 2016, 2, 16069. [Google Scholar] [CrossRef]
  6. Cauble, M.A.; Muckley, M.J.; Fang, M.; Fessler, J.A.; Welch, K.; Rothman, E.D.; Orr, B.G.; Duong, L.T.; Holl, M.M.B. Estrogen depletion and drug treatment alter the microstructure of type I collagen in bone. Bone Rep. 2016, 5, 243–251. [Google Scholar] [CrossRef] [PubMed]
  7. Gaspard, U.J.; Gottal, J.M.; Van den Brûle, F.A. Postmenopausal changes of lipid and glucose metabolism: A review of their main aspects. Maturitas 1995, 21, 171–178. [Google Scholar] [CrossRef] [PubMed]
  8. Ali, D.; Figeac, F.; Caci, A.; Ditzel, N.; Schmal, C.; Kerckhofs, G.; Havelund, J.; Faergeman, N.; Rauch, A.; Tencerova, M.; et al. High-fat diet-induced obesity augments the deleterious effects of estrogen deficiency on bone: Evidence from ovariectomized mice. Aging Cell 2022, 21, e13726. [Google Scholar] [CrossRef]
  9. Wong, S.K.; Chin, K.Y.; Suhaimi, F.H.; Ahmad, F.; Ima-Nirwana, S. The Relationship between Metabolic Syndrome and Osteoporosis: A Review. Nutrients 2016, 8, 347. [Google Scholar] [CrossRef]
  10. Ko, S.H.; Jung, Y. Energy Metabolism Changes and Dysregulated Lipid Metabolism in Postmenopausal Women. Nutrients 2021, 13, 4556. [Google Scholar] [CrossRef]
  11. Tawfik, S.H.; Mahmoud, B.F.; Saad, M.I.; Shehata, M.; Kamel, M.A.; Helmy, M.H. Similar and Additive Effects of Ovariectomy and Diabetes on Insulin Resistance and Lipid Metabolism. Biochem. Res. Int. 2015, 2015, 567945. [Google Scholar] [CrossRef]
  12. Wong, S.K.; Mahmoud, B.F.; Saad, M.I.; Shehata, M.; Kamel, M.A.; Helmy, M.H. Osteoporosis is associated with metabolic syndrome induced by high-carbohydrate high-fat diet in a rat model. Biomed. Pharmacother. 2018, 98, 191–200. [Google Scholar] [CrossRef] [PubMed]
  13. Zhou, J.; Zhang, Q.; Yuan, X.; Wang, J.; Li, C.; Sheng, H.; Qu, S.; Li, H. Association between metabolic syndrome and osteoporosis: A meta-analysis. Bone 2013, 57, 30–35. [Google Scholar] [CrossRef]
  14. Abbasi, M.; Farzam, S.A.; Mamaghani, Z.; Yazdi, Z. Relationship between metabolic syndrome and its components with bone densitometry in postmenopausal women. Diabetes Metab. Syndr. 2017, 11, S73–S76. [Google Scholar] [CrossRef] [PubMed]
  15. Sharma, S.; Tandon, V.R.; Mahajan, S.; Mahajan, V.; Majahan, A. Obesity: Friend or foe for osteoporosis. J. Mid-life Health 2014, 5, 6. [Google Scholar] [CrossRef] [PubMed]
  16. Zong, Q.; Bundkirchen, K.; Neunaber, C.; Noack, S. Are the Properties of Bone Marrow-Derived Mesenchymal Stem Cells Influenced by Overweight and Obesity? Int. J. Mol. Sci. 2023, 24, 4831. [Google Scholar] [CrossRef]
  17. Rolvien, T.; Amling, M. Disuse Osteoporosis: Clinical and Mechanistic Insights. Calcif. Tissue Int. 2021, 110, 592–604. [Google Scholar] [CrossRef]
  18. Calder, P.C.; Ahluwalia, N.; Brouns, F.; Buetler, T.; Clement, K.; Cunningham, K.; Esposito, K.; Jönsson, L.S.; Kolb, H.; Lansink, M.; et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br. J. Nutr. 2011, 106, S5–S78. [Google Scholar] [CrossRef]
  19. Kinjo, M.; Setoguchi, S.; Solomon, D.H. Bone Mineral Density in Adults with the Metabolic Syndrome: Analysis in a Population-Based U.S. Sample. J. Clin. Endocrinol. Metab. 2007, 92, 4161–4164. [Google Scholar] [CrossRef]
  20. Campos, R.M.; de Piano, A.; da Silva, P.L.; Carnier, J.; Sanches, P.L.; Corgosinho, F.C.; Masquio, D.C.; Lazaretti-Castro, M.; Oyama, L.M.; Nascimento, C.M.; et al. The role of pro/anti-inflammatory adipokines on bone metabolism in NAFLD obese adolescents: Effects of long-term interdisciplinary therapy. Endocrine 2012, 42, 146–156. [Google Scholar] [CrossRef]
  21. Dias-Junior, C.A.; Cau, S.B.D.A.; Tanus-Santos, J.E. Papel do óxido nítrico na regulação da circulação pulmonar: Implicações fisiológicas, fisiopatológicas e terapêuticas. J. Bras. Pneumol. 2008, 34, 412–419. [Google Scholar] [CrossRef]
  22. Saltiel, A.R.; Olefsky, J.M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Investig. 2017, 127, 1–4. [Google Scholar] [CrossRef] [PubMed]
  23. Izaola, O.; Luis, D.; Sajoux, I.; Domingo, J.C.; Vidal, M. Inflamación y obesidad (lipoinflamación). Nutr. Hosp. 2015, 31, 2352–2358. [Google Scholar] [PubMed]
  24. Black, D.M.; Rosen, C.J. Postmenopausal Osteoporosis. N. Engl. J. Med. 2016, 374, 254–262. [Google Scholar] [CrossRef]
  25. Aspray, T.J.; Francis, R.M. Treatment of osteoporosis in women intolerant of oral bisphosphonates. Maturitas 2012, 71, 76–78. [Google Scholar] [CrossRef]
  26. Yun, K.J.; Lee, J.G.; Kim, S.S.; Kim, B.H.; Kim, S.J.; Kim, Y.K.; Kim, I.J. Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women. Endocr. J. 2011, 58, 87–93. [Google Scholar]
  27. Malavasi, M.; Louro, R.; Barros, M.B.; Teixeira, L.N.; Peruzzo, D.C.; Joly, J.C.; Martinez, E.F.; Napimoga, M.H. Effects of risedronate on osteoblastic cell cultures. Arch. Oral Biol. 2016, 68, 43–47. [Google Scholar] [CrossRef]
  28. Wang, G.; Zhu, Z.; Lei, C.; Li, M.; Liu, F.; Mao, Y.; Yu, Z.; Liu, M.; Zhao, X.; Tang, T. Low-dose Risedronate Sodium Protects Bone Cells after Abrupt Oestrogen Withdrawal. J. Int. Med. Res. 2012, 40, 1761–1774. [Google Scholar] [CrossRef]
  29. D’Amelio, P.; Grimaldi, A.; Di Bella, S.; Tamone, C.; Brianza, S.Z.M.; Ravazzoli, M.G.A.; Bernabei, P.; Cristofaro, M.A.; Pescarmona, G.P.; Isaia, G. Risedronate Reduces Osteoclast Precursors and Cytokine Production in Postmenopausal Osteoporotic Women. J. Bone Miner. Res. 2007, 23, 373–379. [Google Scholar] [CrossRef]
  30. Ruggiero, S.L.; Dodson, T.B.; Fantasia, J.; Goodday, R.; Aghaloo, T.; Mehrotra, B.; O’Ryan, F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J. Oral Maxillofac. Surg. 2014, 72, 1938–1956. [Google Scholar] [CrossRef]
  31. Ramalho-Ferreira, G.; Faverani, L.P.; Prado, F.B.; Garcia, I.R., Jr.; Okamoto, R. Raloxifene enhances peri-implant bone healing in osteoporotic rats. Int. J. Oral Maxillofac. Surg. 2015, 44, 798–805. [Google Scholar] [CrossRef]
  32. Luvizuto, E.R.; Queiroz, T.P.; Dias, S.M.D.; Okamoto, T.; Dornelles, R.C.M.; Garcia, I.R., Jr.; Okamoto, R. Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene. Arch. Oral Biol. 2010, 55, 52–59. [Google Scholar] [CrossRef] [PubMed]
  33. Faverani, L.P.; Polo, T.O.B.; Ramalho-Ferreira, G.; Momesso, G.A.C.; Hassumi, J.S.; Rossi, A.C.; Freire, A.R.; Prado, F.B.; Luvizuto, E.R.; Gruber, R.; et al. Raloxifene but not alendronate can compensate the impaired osseointegration in osteoporotic rats. Clin. Oral Investig. 2018, 22, 255–265. [Google Scholar] [CrossRef] [PubMed]
  34. Tu, K.N.; Lie, J.D.; Wan, C.K.V.; Cameron, M.; Austel, A.G.; Nguyen, J.K.; Van, K.; Hyun, D. Osteoporosis: A Review of Treatment Options. Pharm. Ther. 2018, 43, 92–104. [Google Scholar]
  35. Gomes-Ferreira, P.H.S.; Micheletti, C.; Frigério, P.B.; de Souza Batista, F.R.; Monteiro, N.G.; Bim-júnior, O.; Okamoto, R. PTH 1-34-functionalized bioactive glass improves peri-implant bone repair in orchiectomized rats: Microscale and ultrastructural evaluation. Biomater. Adv. 2022, 134, 112688. [Google Scholar] [CrossRef] [PubMed]
  36. Delmas, P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359, 2018–2026. [Google Scholar] [CrossRef] [PubMed]
  37. Trovas, G.P.; Lyritis, G.P.; Galanos, A.; Raptou, P.; Constantelou, E. A Randomized Trial of Nasal Spray Salmon Calcitonin in Men With Idiopathic Osteoporosis: Effects on Bone Mineral Density and Bone Markers. J. Bone Miner. Res. 2002, 17, 521–527. [Google Scholar] [CrossRef]
  38. de Oliveira, J.H.A.; Bracco, O.L.; Kayath, M.; Guarniero, R. Teriparatida (PTH[1-34]rh): Uma nova perspectiva no tratamento da osteoporose. Acta Ortop. Bras. 2003, 11, 184–189. [Google Scholar] [CrossRef]
  39. Andrews, E.B.; Gilsenan, A.W.; Midkiff, K.; Sherrill, B.; Wu, Y.; Mann, B.H.; Masica, D. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: Study design and findings from the first 7 years. J. Bone Miner. Res. 2012, 27, 2429–2437. [Google Scholar] [CrossRef]
  40. Wang, P.G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A.J. Nitric oxide donors: Chemical activities and biological applications. Chem. Rev. 2002, 102, 1091–1134. [Google Scholar] [CrossRef]
  41. Bettache, N.; Carter, T.; Corrie, J.E.; Ogden, D.; Trentham, D.R. Photolabile donors of nitric oxide: Ruthenium nitrosyl chlorides as caged nitric oxide. Methods Enzymol. 1996, 268, 266–281. [Google Scholar]
  42. Lunardi, C.N.; Da Silva, R.S.; Bendhack, L.M. New nitric oxide donors based on ruthenium complexes. Braz. J. Med. Biol. Res. 2009, 42, 87–93. [Google Scholar] [CrossRef] [PubMed]
  43. Schwentker, A.; Billiar, T.R. Nitric oxide and wound repair. Surg. Clin. N. Am. 2003, 83, 521–530. [Google Scholar] [CrossRef] [PubMed]
  44. Koyama, A.; Otsuka, E.; Inpue, A.; Hirose, S.; Hagiwara, H. Nitric oxide accelerates the ascorbic acid-induced osteoblastic differentiation of mouse stromal ST2 cells by stimulating the production of prostaglandin E(2). Eur. J. Pharmacol. 2000, 391, 225–231. [Google Scholar] [CrossRef]
  45. Afzal, F.; Polak, J.M.; Lee, D.K. Buttery. Endothelial nitric oxide synthase in the control of osteoblastic mineralizing activity and bone integrity. J. Pathol. 2004, 202, 503–510. [Google Scholar] [CrossRef] [PubMed]
  46. Chae, H.J.; Park, R.K.; Chung, H.T.; Kang, J.S.; Kim, M.S.; Choi, D.Y.; Bang, B.G.; Kim, H.R. Nitric Oxide is a Regulator of Bone Remodelling. J. Pharm. Pharmacol. 1997, 49, 897–902. [Google Scholar] [CrossRef] [PubMed]
  47. Stefanska, A.; Bergmann, K.; Sypniewska, G. Metabolic Syndrome and Menopause. Adv. Clin. Chem. 2015, 72, 1–75. [Google Scholar]
  48. Perry, A.; Wang, X.; Goldberg, R.; Ross, R.; Jackson, L. Androgenic sex steroids contribute to metabolic risk beyond intra-abdominal fat in overweight/obese black and white women. Obesity 2013, 21, 1618–1624. [Google Scholar] [CrossRef]
  49. Janssen, I.; Powell, L.H.; Kazlauskaite, R.; Dugan, S.A. Testosterone and Visceral Fat in Midlife Women: The Study of Women’s Health Across the Nation (SWAN) Fat Patterning Study. Obesity 2009, 18, 604–610. [Google Scholar] [CrossRef]
  50. Caceres, M.; Teran, C.G.; Rodriguez, S.; Medina, M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatr. 2008, 8, 31. [Google Scholar] [CrossRef]
  51. Almeida, M.E.F.; Santos, V.S.; Simão, A.A.; Corrêa, A.D. Dieta de cafeteria com chocolate, amendoim e biscoito: Eficácia na indução do excesso de peso e da dislipidemia em ratos. SaBios-Rev. Saúde Biol. 2015, 10, 15–24. [Google Scholar]
  52. Mellado-Valero, A.; Ferrer-García, J.C.; Calvo-Catalá, J.; Labaig-Rueda, C. Implant treatment in patients with osteoporosis. Med. Oral Patol. Oral Cir. Bucal 2009, 15, e52–e57. [Google Scholar] [CrossRef] [PubMed]
  53. Szulc, P.; Seeman, E.; Duboef, F.; Sornay-Rendi, E.; Delmas, P.D. Bone Fragility: Failure of Periosteal Apposition to Compensate for Increased Endocortical Resorption in Postmenopausal Women. J. Bone Miner. Res. 2006, 21, 1856–1863. [Google Scholar] [CrossRef] [PubMed]
  54. Nishiyama, K.K.; Macdonald, H.M.; Buie, H.R.; Hanley, D.A.; Boyd, S.K. Postmenopausal Women with Osteopenia Have Higher Cortical Porosity and Thinner Cortices at the Distal Radius and Tibia Than Women with Normal aBMD: An In Vivo HR-pQCT Study. J. Bone Miner. Res. 2009, 25, 882–890. [Google Scholar] [CrossRef]
  55. Payne, J.B.; Zachs, N.R.; Reinhardt, R.A.; Nummikoski, P.V.; Patil, K. The association between estrogen status and alveolar bone density changes in postmenopausal women with a history of periodontitis. J. Periodontol. 1997, 68, 24–31. [Google Scholar] [CrossRef] [PubMed]
  56. Oliveira, D.; Hassumi, J.S.; Gomes-Ferreira, P.H.S.; Polo, T.O.B.; Ramalho-Ferreira, G.; Faverani, L.P.; Okamoto, R. Short Term Sodium Alendronate Administration Improves the Peri-Implant Bone Quality in Osteoporotic Animals. J. Appl. Oral Sci. 2017, 25, 42–52. [Google Scholar] [CrossRef] [PubMed]
  57. Jin, J.; Jin, D. [Risedronate inhibits rat bone marrow adipogenesis and reduces RANKL expression in adipocytes]. Nan Fang Yi Ke Da Xue Xue Bao J. South. Med. Univ. 2019, 39, 987–992. [Google Scholar]
  58. Li, M.; Aveyard, J.; Fleming, G.; Curran, J.M.; McBride, F.; Raval, R.; D’sa, R.A. Nitric Oxide Releasing Titanium Surfaces for Antimicrobial Bone-Integrating Orthopedic Implants. ACS Appl. Mater. Interfaces 2020, 12, 22433–22443. [Google Scholar] [CrossRef]
  59. Anastasio, A.T.; Paniagua, A.; Diamond, C.; Ferlauto, H.R.; Fernandez-Moure, J.S. Nanomaterial Nitric Oxide Delivery in Traumatic Orthopedic Regenerative Medicine. Front. Bioeng. Biotechnol. 2021, 8, 592008. [Google Scholar] [CrossRef]
  60. Holt, J.; Hertzberg, B.; Weinhold, P.; Storm, W.; Schoenfisch, M.; Dahners, L. Decreasing Bacterial Colonization of External Fixation Pins Through Nitric Oxide Release Coatings. J. Orthop. Trauma 2011, 25, 432–437. [Google Scholar] [CrossRef]
  61. Aguirre, J.; Buttery, L.; O’Shaughnessy, M.; Afzal, F.; de Marticorena, I.F.; Hukkanen, M.; Huang, P.; MacIntyre, I.; Polak, J. Endothelial Nitric Oxide Synthase Gene-Deficient Mice Demonstrate Marked Retardation in Postnatal Bone Formation, Reduced Bone Volume, and Defects in Osteoblast Maturation and Activity. Am. J. Pathol. 2001, 158, 247–257. [Google Scholar] [CrossRef]
  62. Otsuka, E.; Hirano, K.; Matsushita, S.; Inoue, A.; Hirose, S.; Yamaguchi, A.; Hagiwara, H. Effects of nitric oxide from exogenous nitric oxide donors on osteoblastic metabolism. Eur. J. Pharmacol. 1998, 349, 345–350. [Google Scholar] [CrossRef] [PubMed]
  63. Jamal, S.A.; Hamilton, C.J.; Black, D.; Cummings, S.R. The effects of organic nitrates on osteoporosis: A randomized controlled trial [ISRCTN94484747]. Trials 2006, 7, 10–14. [Google Scholar] [CrossRef]
  64. Mancini, L.; Moradi_Bidhendi, N.; Becherrini, L.; Martineti, V.; MacIntyre, I. The biphasic effects of nitric oxide in primary rat osteoblasts are cGMP dependent. Biochem. Biophys. Res. Commun. 2000, 274, 477–481. [Google Scholar] [CrossRef]
  65. Kaneko, K.; Miyamoto, Y.; Ida, T.; Morita, M.; Yoshimura, K.; Nagasaki, K.; Toba, K.; Sugisaki, R.; Motohashi, H.; Akaike, T.; et al. 8-Nitro-cGMP suppresses mineralization by mouse osteoblasts. J. Clin. Biochem. Nutr. 2022, 71, 191–197. [Google Scholar] [CrossRef]
  66. Saura, M.; Tarin, C.; Zaragoza, C. Recent Insights into the Implication of Nitric Oxide in Osteoblast Differentiation and Proliferation during Bone Development. J. Clin. Biochem. Nutr. 2010, 10, 624–632. [Google Scholar] [CrossRef]
  67. Kaneko, K.; Miyamoto, Y.; Tsukuura, R.; Sasa, K.; Akaike, T.; Fujii, S.; Yoshimura, K.; Nagayama, K.; Hoshino, M.; Inoue, S.; et al. 8-Nitro-cGMP is a promoter of osteoclast differentiation induced by RANKL. Nitric Oxide 2018, 72, 46–51. [Google Scholar] [CrossRef]
Ijms 24 16153 g001
Figure 1. Clinical data graphics of the SHAM, OVX + HD, and OVX + HD + RIS groups during the T1, T2, and T3 periods. *: statistically significant difference.
Figure 1. Clinical data graphics of the SHAM, OVX + HD, and OVX + HD + RIS groups during the T1, T2, and T3 periods. *: statistically significant difference.
Ijms 24 16153 g001
Ijms 24 16153 g002
Figure 2. Mean removal torque values between the SHAM, OVX + HD, and OVX + HD + RIS groups. Mean values: SHAM CONV (102.4 N/cm ± 13.0), SHAM TE10 (101.6 N/cm ± 12.7), SHAM TE100 122.4 N/cm ± 17.4), OVX + HD CONV (48 N/cm ± 5.8), OVX + HD TPY10 (74 N/cm ± 6.8), OVX + HD TE100 (32 N/cm ± 12.1), OVX + HD + RIS CONV (67.2 N/cm ± 24.2), OVX + HD + RIS TE10 (69.6 N/cm ± 28.8) e OVX + HD + RIS TE100 (69.2 N/cm ± 15.7). *: statistically significant difference.
Figure 2. Mean removal torque values between the SHAM, OVX + HD, and OVX + HD + RIS groups. Mean values: SHAM CONV (102.4 N/cm ± 13.0), SHAM TE10 (101.6 N/cm ± 12.7), SHAM TE100 122.4 N/cm ± 17.4), OVX + HD CONV (48 N/cm ± 5.8), OVX + HD TPY10 (74 N/cm ± 6.8), OVX + HD TE100 (32 N/cm ± 12.1), OVX + HD + RIS CONV (67.2 N/cm ± 24.2), OVX + HD + RIS TE10 (69.6 N/cm ± 28.8) e OVX + HD + RIS TE100 (69.2 N/cm ± 15.7). *: statistically significant difference.
Ijms 24 16153 g002
Ijms 24 16153 g003
Figure 3. Relative gene expression of the OPG gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.000), SHAM TE10 (0.662), SHAM TE100 (0.363), OVX + HD CONV (0.650), OVX + HD TE10 (6.841), OVX + HD TE100 (1), OVX + HD + RIS CONV (0.623), OVX + HD + RIS TE10 (4.271), and OVX + HD + RIS TE100 (0.549). *: statistically significant difference.
Figure 3. Relative gene expression of the OPG gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.000), SHAM TE10 (0.662), SHAM TE100 (0.363), OVX + HD CONV (0.650), OVX + HD TE10 (6.841), OVX + HD TE100 (1), OVX + HD + RIS CONV (0.623), OVX + HD + RIS TE10 (4.271), and OVX + HD + RIS TE100 (0.549). *: statistically significant difference.
Ijms 24 16153 g003
Ijms 24 16153 g004
Figure 4. Relative gene expression of the RANKL gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.034), SHAM TE10 (1.000), SHAM TE100 (0.637), OVX + HD CONV (2.255), OVX + HD TE10 (15.004), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (4.674), OVX + HD + RIS TE10 (3.722), and OVX + HD + RIS TE100 (1.782). *: statistically significant difference.
Figure 4. Relative gene expression of the RANKL gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.034), SHAM TE10 (1.000), SHAM TE100 (0.637), OVX + HD CONV (2.255), OVX + HD TE10 (15.004), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (4.674), OVX + HD + RIS TE10 (3.722), and OVX + HD + RIS TE100 (1.782). *: statistically significant difference.
Ijms 24 16153 g004
Ijms 24 16153 g005
Figure 5. Relative gene expression of the ALP gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.010), SHAM TE10 (2.058), SHAM TE100 (4.105), OVX + HD CONV (6.609), OVX + HD TE10 (0.354), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (6.550), OVX + HD + RIS TE10 (2.431), and OVX + HD + RIS TE100 (0.779). *: statistically significant difference.
Figure 5. Relative gene expression of the ALP gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.010), SHAM TE10 (2.058), SHAM TE100 (4.105), OVX + HD CONV (6.609), OVX + HD TE10 (0.354), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (6.550), OVX + HD + RIS TE10 (2.431), and OVX + HD + RIS TE100 (0.779). *: statistically significant difference.
Ijms 24 16153 g005
Ijms 24 16153 g006
Figure 6. Relative gene expression of the IBSP gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (0.779), SHAM TE10 (1.425), SHAM TE100 (3.017), OVX + HD CONV (1.865), OVX + HD TE10 (0.519), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (3.127), OVX + HD + RIS TE10 (3.400), and OVX + HD + RIS TE100 (1.492). *: statistically significant difference.
Figure 6. Relative gene expression of the IBSP gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (0.779), SHAM TE10 (1.425), SHAM TE100 (3.017), OVX + HD CONV (1.865), OVX + HD TE10 (0.519), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (3.127), OVX + HD + RIS TE10 (3.400), and OVX + HD + RIS TE100 (1.492). *: statistically significant difference.
Ijms 24 16153 g006
Ijms 24 16153 g007
Figure 7. Relative gene expression of the VEGF gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.071), SHAM TE10 (5.525), SHAM TE100 (0.360), OVX + HD CONV (0.405), OVX + HD TE10 (0.563), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (0.467), OVX + HD + RIS TE10 (3.666), and OVX + HD + RIS TE100 (1.501). *: statistically significant difference.
Figure 7. Relative gene expression of the VEGF gene for the CONV, TE 10, and TE 100 groups. Mean values of: SHAM CONV (1.071), SHAM TE10 (5.525), SHAM TE100 (0.360), OVX + HD CONV (0.405), OVX + HD TE10 (0.563), OVX + HD TE100 (1.000), OVX + HD + RIS CONV (0.467), OVX + HD + RIS TE10 (3.666), and OVX + HD + RIS TE100 (1.501). *: statistically significant difference.
Ijms 24 16153 g007
Ijms 24 16153 g008
Figure 8. Layer−by−layer technique process.
Figure 8. Layer−by−layer technique process.
Ijms 24 16153 g008
Table 1. Experimental groups and subgroups according to systemic impairment and type of implant to be installed. Each group, as mentioned above, was divided according to systemic impairment, diet, and drug treatment (SHAM, OVX + DH and OVX + DH + RIS), with 24 animals per group. These groups were subdivided into 3 other groups according to the type of implant to be installed (CONV, TERPY 10 μM, and TERPY 100 μM), with 8 rats per subgroup.
Table 1. Experimental groups and subgroups according to systemic impairment and type of implant to be installed. Each group, as mentioned above, was divided according to systemic impairment, diet, and drug treatment (SHAM, OVX + DH and OVX + DH + RIS), with 24 animals per group. These groups were subdivided into 3 other groups according to the type of implant to be installed (CONV, TERPY 10 μM, and TERPY 100 μM), with 8 rats per subgroup.
GroupsType of ImplantDescription
SHAMCONV (n = 8)Rats subjected to fictitious ovariectomy surgery
TERPY 10 μM (n = 8)
TERPY 100 μM (n = 8)
OVX + HDCONV (n = 8)Rats subjected to ovariectomy surgery and hypercaloric diet
TERPY 10 μM (n = 8)
TERPY 100 μM (n = 8)
OVX + HD + RISCONV (n = 8)Rats subjected to ovariectomy surgery and hypercaloric diet and treated with sodium risedronate 0.35 mg/kg
TERPY 10 μM (n = 8)
TERPY100 μM (n = 8)
Table 2. OVX + HD and OVX + HD + RIS diets during the experiment. Each day during the experiment, each animal received 10 g of Stuffed Cracker, 10 g of Waffer, and 10 g of Corn Chips, and unrestricted access to water with 24 g of Sucrose per 200 mL.
Table 2. OVX + HD and OVX + HD + RIS diets during the experiment. Each day during the experiment, each animal received 10 g of Stuffed Cracker, 10 g of Waffer, and 10 g of Corn Chips, and unrestricted access to water with 24 g of Sucrose per 200 mL.
Food Quantity (g/rat/Day)
Stuffed Cracker10
Wafer10
Corn Chips10
Water + sucrose (12%)24 g + 200 mL of water
Table 3. Taqman probes for Real-Time PCR.
Table 3. Taqman probes for Real-Time PCR.
GeneGene NameIdentification
OPGTnfrsf11bRn00563499_m1
RANKLTnfrsf11Rn00589289_m1
ALPALPLRn00564931_m1
IBSPIBSPRn00561414_m1
VEGFVEGFARn01511602_m1
B2MB2MRn00560865_m1
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Inoue, B.K.N.; Paludetto, L.V.; Monteiro, N.G.; Batista, F.R.d.S.; Kitagawa, I.L.; da Silva, R.S.; Antoniali, C.; Lisboa Filho, P.N.; Okamoto, R. Synergic Action of Systemic Risedronate and Local Rutherpy in Peri-implantar Repair of Ovariectomized Rats: Biomechanical and Molecular Analysis. Int. J. Mol. Sci. 2023, 24, 16153. https://doi.org/10.3390/ijms242216153

AMA Style

Inoue BKN, Paludetto LV, Monteiro NG, Batista FRdS, Kitagawa IL, da Silva RS, Antoniali C, Lisboa Filho PN, Okamoto R. Synergic Action of Systemic Risedronate and Local Rutherpy in Peri-implantar Repair of Ovariectomized Rats: Biomechanical and Molecular Analysis. International Journal of Molecular Sciences. 2023; 24(22):16153. https://doi.org/10.3390/ijms242216153

Chicago/Turabian Style

Inoue, Bruna Kaori Namba, Laura Vidoto Paludetto, Naara Gabriela Monteiro, Fábio Roberto de Souza Batista, Igor Lebedenco Kitagawa, Roberto Santana da Silva, Cristina Antoniali, Paulo Noronha Lisboa Filho, and Roberta Okamoto. 2023. "Synergic Action of Systemic Risedronate and Local Rutherpy in Peri-implantar Repair of Ovariectomized Rats: Biomechanical and Molecular Analysis" International Journal of Molecular Sciences 24, no. 22: 16153. https://doi.org/10.3390/ijms242216153

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop